Sugi Predict

Sugi Predict / Compounds / SCHEMBL14616893

SCHEMBL14616893

SCHEMBL14616893

NC1CCc2cc(Br)cnc21

nearest known ligand 0.35

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ FNTA P49354 15/20 0.33
▸ FNTB P49356 15/20 0.33
▸ CTSD P07339 2/20 0.33
▸ BACE1 P56817 2/20 0.33
▸ HRAS P01112 1/20 0.32
▸ KRAS P01116 1/20 0.32
▸ ABCB1 P08183 1/20 0.32
▸ OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30702209 1.00 HTT (0.35) HTTKMT2AFNTAFNTBCTSD
SCHEMBL16809891 0.89 BACE1 (0.35) HTTKMT2AFNTAFNTBBACE1
Hydrochloric Acid SCHEMBL16793617 0.88 BACE1 (0.34) HTTKMT2AFNTAFNTBBACE1
Hydrochloric Acid SCHEMBL16793574 0.88 BACE1 (0.34) HTTKMT2AFNTAFNTBBACE1
Hydrochloric Acid SCHEMBL16793573 0.88 BACE1 (0.34) HTTKMT2AFNTAFNTBBACE1
SCHEMBL18650419 0.79 AKR1B1 (0.34) HTTKMT2AFNTAFNTBCTSD
SCHEMBL6845123 0.78 NOS3 (0.35) FNTAFNTB
SCHEMBL12611750 0.78 BACE1 (0.38) BACE1
SCHEMBL14616897 0.78 FNTA (0.33) HTTKMT2AFNTAFNTBHRAS
SCHEMBL9403366 0.78 FNTA (0.33) FNTAFNTBHRASKRASABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028348-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS INC (US) 2026-01-29 — — US disclosed
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-12-30 — — US disclosed
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2025-11-27 — — US disclosed
EP-4594307-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2025-08-06 — — EP disclosed
US-20250154111-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-05-15 — — US disclosed
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-02-20 — — US disclosed
EP-4491622-A2 CARDIAC SARCOMERE INHIBITORS Cytokinetics, Inc. (US) 2025-01-15 — — EP disclosed
EP-3740481-B9 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-10-23 — — EP disclosed
US-12065436-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-08-20 — — US disclosed
WO-2024148191-A1 MODULATORS OF TNF-α ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2024-07-11 — — WO disclosed
EP-3740481-A1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS Cytokinetics, Inc. (US) 2020-11-25 — — EP disclosed
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed
WO-2019144041-A1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. (US) 2019-07-25 — — WO disclosed
US-20180000795-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-01-04 — — US disclosed
EP-3247354-A1 FACTOR XIA INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-11-29 — — EP disclosed
WO-2016118403-A1 FACTOR XIA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-07-28 — — WO disclosed
EP-2668155-B1 NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-11-26 — — EP disclosed
US-20130018055-A1 NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-01-17 — — US disclosed
US-20130018055-A1 NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10836755-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 HTT 3581/4885KMT2A 3501/4885FNTA 3967/4885
US-12065436-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 HTT 3581/4885KMT2A 3501/4885FNTA 3967/4885
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof TNNT2, TNNI3, TNNC1 HTT 1170/4885KMT2A 3822/4885FNTA 3386/4885
US-20130018055-A1 NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES CYP1A1, AHR, CYP1B1 HTT 2026/4885KMT2A 1277/4885FNTA 3399/4885
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 HTT 3581/4885KMT2A 3501/4885FNTA 3967/4885
US-20250154111-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, SDHA HTT 343/4885KMT2A 3454/4885FNTA 2280/4885
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, SDHA HTT 343/4885KMT2A 3454/4885FNTA 2280/4885
US-20260028348-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, TNFRSF1A, TNFRSF9 HTT 2924/4885KMT2A 4607/4885FNTA 1285/4885
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 HTT 3581/4885KMT2A 3501/4885FNTA 3967/4885
US-20180000795-A1 FACTOR XIa INHIBITORS F11, SERPINC1, TFPI HTT 4136/4885KMT2A 1209/4885FNTA 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.